• 1
    Patek AJ, Taylor FHL. Hemophilia. II. Some properties of a substance obtained from normal plasma which is effective in accelerating the coagulation of hemophilic blood. J Clin Investigation 1937; 16: 11324.
  • 2
    Biggs R. Thirty years of haemophilia treatment in Oxford. Br J Haematol 1967; 13: 45263.
  • 3
    Bidwell E. The purification of bovine antihaemophilic globulin. Br J Haematol 1955; 1: 3545.
  • 4
    Macfarlane RG, Biggs R, Bidwell E. Bovine antihaemophilic globulin in the treatment of haemophilia. Lancet 1954; i: 13169.
  • 5
    Tansey EM, Christie DA (eds). Haemophilia: Recent history of clinical management, Wellcome Witnesses to Twentieth Century Medicine, Vol. 4. London: The Wellcome Trust, 1999. (ISBN 978 184129 0089), (a) Bidwell E quoted on page 14 and (b) Rizza C quoted on page 16.
  • 6
    Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 3141.
  • 7
    Hay CR. Porcine factor VIII: past, present and future. Haematologica 2000; 85(Suppl 1): 214.
  • 8
    Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 2(Suppl 1): 1021.
  • 9
    Ewenstein BM, Avorn J, Putnam KG, Bohn RL. Porcine factor VIII: pharmacoeconomics of inhibitor therapy. Haemophilia 2002; 8(Suppl 1): 136.
  • 10
    Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PA. Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine factor VIII by home therapy. Blood 1990; 76: 8826.
  • 11
    Vyas P, Pasi J, Lee CA. Successful long-term treatment with porcine factor VIII of a patient with haemophilia and an inhibitor to factor VIII. Haemophilia 1996; 2: 2403.
  • 12
    Hermans C, Owens D, Longo G, Morfini M, Lee CA. Single-dose pharmacokinetics of porcine factor VIII (Hyate C). Thromb Haemost 2002; 87: 3523.
  • 13
    Lollar P, Parker CG, Tracy RP. Molecular characterization of commercial porcine factor VIII concentrate. Blood 1988; 71: 13743.
  • 14
    Brettler DB, Forsberg AD, Levine PH et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 13815.
  • 15
    Hay CR, Lozier JN, Lee CA et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 259.
  • 16
    Gringeri A, Santagostino E, Tradati F, Giangrande PL, Mannucci PM. Adverse effects of treatment with porcine factor VIII. Thromb Haemost 1991; 65: 2457.
  • 17
    Altieri DC, Capitanio AM, Mannucci PM. von Willebrand factor contaminating porcine factor VIII concentrate (Hyate C) causes platelet aggregation. Br J Haematol 1986; 63: 70311.
  • 18
    Pareti FI, Mazzucato M, Bottini E, Mannucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIa complex. Br J Haematology 1992; 82: 816.
  • 19
    Freedman J, Mody M, Lazarus AH et al. Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol 2002; 69: 1929.
  • 20
    Giangrande PL, Kessler CM, Jenkins CE, Weatherill PJ, Webb PD. Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia 2002; 8: 798801.
  • 21
    Soucie JM, Erdman DD, Evatt BL et al. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate. Transfusion 2000; 40: 70811.
  • 22
    Takefman DM, Wong S, Maudru T, Peden K, Wilson CA. Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII. J Virol 2001; 75: 45517.
  • 23
    Heneine W, Switzer WM, Soucie JM et al. Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. J Infect Dis 2001; 183: 64852.
  • 24
    Mosesson MW, Fass DN, Lollar P et al. Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis. J Clin Investigation 1990; 85: 198390.
  • 25
    Toschi V. OBI-1, porcine recombinant factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human factor VIII. Curr Opin Mol Ther 2010; 12: 61725.
  • 26
    Lollar P. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 2000; 85(Suppl 1): 268.
  • 27
    Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 5648.
  • 28
    Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 2009; 102: 3541.
  • 29
    Van C, Monahan PE, Nichols TC, Velander WH. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide. Haemophilia 2004; 10(Suppl 4): 706.
  • 30
    Gill GC, Velander WH, Van Cott KE. Analysis of the N-glycans of recombinant factor IX purified from transgenic pig milk. Glycobiology 2008; 18: 52639.